Loading organizations...
§ Private Profile · Oxford, Oxfordshire, United Kingdom
Oxford Endovascular is a technology company.
Oxford Endovascular Ltd is a spin-out from Oxford University, working to prevent brain haemorrhage by curing brain aneurysms, a condition that affects 1 in 50 persons.
Oxford Endovascular has raised $10.0M across 1 funding round.
Oxford Endovascular has raised $10.0M in total across 1 funding round.
Oxford Endovascular has raised $10.0M across 1 funding round. Most recently, it raised $10.0M Series A in April 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 1, 2021 | $10M Series A | Parkwalk Advisors, Martin Diggle | Borealis Ventures, Oxford Science Enterprises, Norcliffe Capital, University OF Oxford, Additio Investment Group, Oxford Investment Consultants, Perivoli Innovations | Announced |
Oxford Endovascular has raised $10.0M in total across 1 funding round.
Oxford Endovascular's investors include Parkwalk Advisors, martin diggle, Borealis Ventures, Oxford Science Enterprises, Norcliffe Capital, University of Oxford, Additio Investment Group, Oxford Investment Consultants, Perivoli Innovations.
Oxford Endovascular is a medtech startup spun out from Oxford University in 2015, developing OxiFlow, a next-generation flow-diverter microstent to treat brain aneurysms and prevent ruptures that cause brain hemorrhage.[1][2][3] Affecting 1 in 50 people, aneurysms represent a $1-3 billion market growing rapidly; OxiFlow uses origami-inspired engineering for precise, safe deployment via minimally invasive groin access, reducing complications and enabling treatment for more patients.[1][2][4] The company has raised over $10 million (£8 million Series A+ in 2021), including from Parkwalk Advisors, Oxford Science Enterprises, and a Horizon 2020 EU grant, funding device completion and first-in-human trials.[1][2][3]
It serves neurosurgeons and patients with intracranial aneurysms, solving placement failures, vessel mismatch, and multi-device needs of current stents by conforming better and deploying accurately.[1][3][4]
Founded in 2015 as an Oxford University spin-out, Oxford Endovascular emerged from collaboration between James Byrne, a professor of neuroradiology with 30+ years treating aneurysms and training MDs, and Zhong You, a professor of engineering science expert in origami structures and minimally invasive devices funded by the Wellcome Trust.[1][2] The idea stemmed from Byrne's pioneering aneurysm treatments and You's "origami engineering" to create shape-memory, laser-cut metal alloy stents that expand precisely post-catheter delivery.[1][3][6]
Early traction included patents in Europe, US, China, and Japan, plus a Horizon 2020 grant after expert due diligence; a pivotal 2021 Series A+ round (£8M led by Parkwalk Advisors) advanced OxiFlow toward human trials.[1][2][3]
Oxford Endovascular rides the neurovascular medtech boom, fueled by aging populations, rising aneurysm prevalence (1 in 50), and demand for minimally invasive treatments amid a $3B+ flow-diverter market.[1][2][4] Timing aligns with advances in shape-memory alloys, laser-cutting, and origami-inspired robotics—from space tech to biomed—enabling compact, precise devices.[3][4][6] Favorable forces include regulatory paths (FDA/CE Mark trials post-first-in-human) and investor appetite for university spin-outs, amplified by EU/UK funding.[1][2][3] It influences the ecosystem by validating cross-disciplinary innovation (medicine + engineering), potentially lowering brain hemorrhage deaths/disability while expanding treatable cases.
Oxford Endovascular is primed for clinical milestones: first-in-human data soon, followed by larger FDA/CE trials and Series B funding to commercialize OxiFlow.[2][3] Trends like AI-guided deployments and personalized stents will accelerate its path, with market growth to $3B+ favoring early movers addressing unmet needs.[1][2][4] Its influence may evolve into a neurovascular leader, spinning off origami tech for other vessels, tying back to its university roots in preventing a condition killing/disabling thousands yearly.[1][3]